Rhino Biotech Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RBRXF research report →
Companyir.rhinobiotech.com
Rhino Biotech Limited intends to develop plant and fungi derived nutraceuticals, and preventative and curative biopharmaceuticals. The company was formerly known as Eurasia Energy Limited and changed its name to Rhino Biotech Limited in September 2021. Rhino Biotech Limited was incorporated in 2003 and is based in South Hill, Anguilla.
- CEO
- Nicholas W. Baxter
- IPO
- 2005
- Employees
- 1
- HQ
- South Hill, AI
Price Chart
Valuation
- Market Cap
- $3.10K
- P/E
- -0.16
- P/S
- 0.00
- P/B
- -0.06
- EV/EBITDA
- -2.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 42.73%
- ROIC
- 695.71%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-21,233 · -3.97%
- EPS
- $-0.00 · 0.00%
- Op Income
- $-21,233
- FCF YoY
- 22.60%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.19
- Avg Volume
- 1.27K
Get TickerSpark's AI analysis on RBRXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our RBRXF Coverage
We haven't published any research on RBRXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RBRXF Report →